BioSpace News Archive

By End User, Diagnostic Laboratories And Hospitals Are Expected To Remain Dominant In Antimicrobial Susceptibility Test Market During Forecast Period.

Black Americans (63%) are significantly more likely than Hispanic Americans (49%) and White Americans (47%) to have no awareness of celiac disease and/or gluten-sensitivity, suggesting potential health inequities in both diagnosis and treatment, according to a nationwide benchmark survey conducted by The Harris Poll on behalf of Beyond Celiac, the leading catalyst for a celiac disease cure.

Incyte announced that it will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 12:30 p.m. in New York.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the addition of five Charles River Accelerator and Development Lab (CRADL™) locations in California and Washington.

The Social Science Research Council (SSRC) announced it will provide an initial USD 7.2 million in direct research funds to 12 teams working in 17 countries in order to better understand how health mis- and disinformation spreads, how to combat it, and how to build stronger information systems, while increasing Covid-19 vaccination rates.

LimFlow SA today announced the appointment of Jenny Gaffney as Vice President, Health Economics and Reimbursement.

New scientific findings offer hope and a natural solution to those who suffer from sensations of crawling, pulling, throbbing, aching and itching in the legs, often resulting in sleep disruption and the uncontrollable urge to move.

Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that it has entered into a distribution agreement with BIOASIA PTE LTD (“Bioasia”), a medical diagnostics distributor located in Singapore.

Researcher from Cytimmune Sciences, a clinical-stage biotechnology company, presented new data on the company’s novel cancer nanomedicines at the Cytokine Drug Development Conference held in Boston, Massachusetts on July 26-28.

The National Comprehensive Cancer Network (NCCN) recently announced new guidelines that recommend testing for all patients diagnosed with colon cancer.